Causal treatment of dyspnea in a hospice patient — a case study
Abstract
The paper presents the case of a 60-year-old, long-term tobacco smoker, after completed treatment of lung cancer, with chronic respiratory insufficiency and severe COPD, who presented severe dyspnea. An additional diagnosis, that was made during the care, was invasive pulmonary aspergillosis. It is commonly believed that cancer is the most debilitating disease of the patient, and its cure guarantees a return to health and normal life. In this case, however the effectiveness of oncological treatment was not correlated with good quality of life. Severe dyspnea was associated with chronic respiratory failure in the course of severe COPD and was accompanied by an invasive pulmonary aspergillosis.
Keywords: dyspneaCOPDcomplication of lung cancer treatmentpulmonary aspergillosis
References
- Siemińska A, Kubiak A, Bobowicz M, et al. Współwystępowanie raka płuca i przewlekłej obturacyjnej choroby płuc. Pol Med Paliat. 2006; 5(2).
- Rzyman W. Rak płuca. Forum Med Rodzinnej. 2008; 2(6): 407–419.
- Leppert W, Nowakowska E. Rola radioterapii w leczeniu objawów zaawansowanej choroby nowotworowej. Med Paliat Praktyce. 2008; 2: 33–47.
- Modlińska A, Buss T, Lichodziejewska-Niemierko M. Opieka paliatywna w przewlekłej chorobie obturacyjnej płuc (POChP). Pneumonol Alergol Pol. 2007; 75(4): 383–388.
- Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Respirology. 2017; 22(3): 575–601.
- García-Sidro P, Naval E, Martinez Rivera C, et al. The CAT (COPD Assessment Test) questionnaire as a predictor of the evolution of severe COPD exacerbations. Respir Med. 2015; 109(12): 1546–1552.
- Jassem E. Chory na przewlekłą obturacyjną chorobę płuc (POChP) w opiece lekarza rodzinnego. Pneumonol Alergol Pol. 2014; 82(II).
- Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014(3): CD010115.
- Cosío BG, Shafiek H, Iglesias A, et al. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. Chest. 2016; 150(1): 123–130.
- Ergan B, Nava S. Long-Term Oxygen Therapy in COPD Patients Who Do Not Meet the Actual Recommendations. COPD. 2017; 14(3): 351–366.
- Śliwiński P, Górecka D, Jassem E, et al. Zalecenia Polskiego Towarzystwa Chorób Płuc dotyczące rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc. Pneumonol Alergol Pol. 2014; 82(3): 227–263.
- Biliński P, Sferyńska I, Warzocha K. Diagnostyka i leczenie układowych zakażeń grzybiczych w onkohematologii. Onkol Prak Klin. 2008; 4: 15–24.
- Khasawneh F, Mohamad T, Moughrabieh MK, et al. Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome. J Crit Care. 2006; 21(4): 322–327.
- Tamura A, Suzuki J, Fukami T, et al. Chronic pulmonary aspergillosis as a sequel to lobectomy for lung cancer. Interact Cardiovasc Thorac Surg. 2015; 21(5): 650–656.
- Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J. 2011; 37(4): 865–872.
- Horinouchi H, Yamao S, Gotoh S, et al. [Two cases of invasive pulmonary aspergillosis mimicking pneumonia in lung cancer patients]. Nihon Kokyuki Gakkai Zasshi. 2009; 47(9): 786–792.
- Kędziora K, Słomiński JM, Gil K, et al. Inwazyjna grzybica kropidlakowa zatok przynosowych, płuc i mózgowia. Pneumonol Alergol Pol. 2008; 76(5): 400–406.
- Curbelo J, Galván JM, Aspa J. Updates on Aspergillus, Pneumocystis and other opportunistic pulmonary mycoses. Arch Bronconeumol. 2015; 51(12): 647–653.
